Clinical Trial Update: Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing immunotherapy BHT-3009 alone or combined with atorvastatin in patients with multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• BHT-3009
• Lipitor (atorvastatin)

Snippet

Sponsor: Bayhill Therapeutics | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED